26 citations,
September 2012 in “Journal of The American Academy of Dermatology” Patients with rapidly progressive alopecia areata often have a better outlook and shorter disease duration, with regrown fine hairs and no past alopecia being positive signs.
April 2023 in “Journal of Investigative Dermatology” This study investigated the role of CD8+ effector memory cells re-expressing CD45RA (TEMRA) in rapidly progressive alopecia areata (RPAA) and their potential to predict therapeutic outcomes following intravenous corticosteroid pulse therapy (IVPT). Involving 26 RPAA patients, the study found that TEMRA cells were significantly increased in non-responders (those with < 50% hair regrowth) compared to responders, both before and after IVPT. Non-responders' TEMRA cells exhibited 3.3-fold greater cytotoxicity when exposed to trichohyalin. Histological analysis showed a higher proportion of TEMRA cells in non-responders' peribulbar regions, correlating with their frequency in peripheral blood mononuclear cells (r = 0.74). These results suggest that monitoring TEMRA cells could help evaluate disease activity and predict therapeutic outcomes in RPAA.
8 citations,
July 2018 in “The Journal of Dermatology” Current corticosteroid pulse therapy is not very effective for severe rapidly progressive alopecia areata.
2 citations,
June 2023 in “Skin Research and Technology” Yellow dots and short vellus hairs are the most common signs of Alopecia Areata (AA), and trichoscopy can help diagnose AA and track treatment progress.